NCT06520683 - Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2030

Conditions

Colorectal CancerMicrosatellite Instability High

Interventions

DRUG

Tislelizumab

\- Tislelizumab 200mg (day 1 and day 22), administered after surgery

DRUG

Adjuvant chemotherapy

"* Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine."

Trial Locations (1)

RECRUITING

Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651, Guangzhou